Jan 23 (Reuters) - Ascentage Pharma 6855.HK said on Thursday it aims to raise $126.4 million in an initial public offering in the U.S., becoming the first sizeable Chinese firm to seek a listing in the United States this year.
(Reporting by Gursimran Kaur in Bengaluru; Editing by Subhranshu Sahu)
((GursimranKaur.Mehar@thomsonreuters.com, https://x.com/GursimranKMehar;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。